From USFDA
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Metformin Hydrochloride Extended‐Release Tablets USP, 500 mg and 1000 mg, the generic version of Glumetza1 Extended‐Release Tablets, 500 mg and 1000 mg, of Salix Pharmaceuticals Inc.According to IQVIATM sales data for the 12‐month period ending September 2019, the Glumetza Tablets, 500 mg and 1000 mg market2 achieved annual sales of approximately $226.7 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
